OpenCapital
Earnings
Stock Screener
Metrics
/
Stocks
Connect AI
Toggle navigation menu
Stocks
ALN
Alnylam Pharmaceuticals
Business Segments
Products & Services
Liabilities related to the sale of future royalties and development funding
Liabilities related to the sale of future royalties and development funding
Alnylam Pharmaceuticals
·
Products & Services
·
2 segments
·
Rolls up to
Liabilities related to the sale of future royalties and development funding
Breakdown
Segments
Vutrisiran
View metric
Zilebesrian
View metric
Quarterly
Annual
TTM
Segment
Q4 '25
Q1 '26
Vutrisiran
$94.50M
$98.50M
Zilebesrian
$6.80M
$7.50M
Total
$220.07M
$227.49M